drugset / Trial / NCT05723432
KD6001 in Combination With Anti-PD-1 Antibody in Patients With Advanced Melanoma
NaSingle-groupOpen-labelTreatment
Summary
This is a phase 1b/2, open label study to evaluate the safety, tolerability, pharmacokinetics and initial efficacy of KD6001 in combination with toripalimab in patients with advanced melanoma.
Timeline
- Start
- 2023-03-22
- Primary completion
- 2024-12-31
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KD6001 | Unknown | — | Intravenous |
| Subject | Toripalimab | Monoclonal antibody | — | Intravenous |